WEST PHARMACEUTICAL SERVICES, INC. Increase (Decrease) in Contract with Customer, Asset
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Increase (Decrease) in Contract with Customer, Asset of $5.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2026-07-23
- WEST PHARMACEUTICAL SERVICES, INC. increase (decrease) in contract with customer, asset for the quarter ending 2026-06-30 was $1.80M, a 14.29% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. increase (decrease) in contract with customer, asset for the quarter ending 2026-03-31 was $3.50M, a 40.00% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. increase (decrease) in contract with customer, asset for the quarter ending 2025-12-31 was -$15.60M.
- WEST PHARMACEUTICAL SERVICES, INC. increase (decrease) in contract with customer, asset for the quarter ending 2025-09-30 was -$400.00K, a 102.03% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. increase (decrease) in contract with customer, asset for fiscal 2025 was -$11.40M, a 733.33% decline from fiscal 2024.
- WEST PHARMACEUTICAL SERVICES, INC. increase (decrease) in contract with customer, asset for fiscal 2024 was $1.80M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $5.30M 10-Q · filed 2026-07-23 | -$10.30M derived: sum of 3 quarters · filed 2026-07-23 | -$10.70M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $3.50M 10-Q · filed 2026-04-23 | -$12.10M derived: sum of 2 quarters · filed 2026-04-23 | -$12.50M derived: sum of 3 quarters · filed 2026-04-23 | -$10.40M derived: sum of 4 quarters · filed 2026-04-23 |
| 2025-12-31 | -$15.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$16.00M derived: sum of 2 quarters · filed 2026-02-17 | -$13.90M derived: sum of 3 quarters · filed 2026-02-17 | -$11.40M 10-K · filed 2026-02-17 |
| 2025-09-30 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $1.70M derived: sum of 2 quarters · filed 2025-10-23 | $4.20M 10-Q · filed 2025-10-23 | -$14.80M derived: sum of 4 quarters · filed 2025-10-23 |
| 2025-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-24 | $4.60M 10-Q · filed 2025-07-24 | -$14.40M derived: sum of 3 quarters · filed 2025-07-24 | $5.30M derived: sum of 4 quarters · filed 2025-07-24 |
| 2025-03-31 | $2.50M 10-Q · filed 2025-04-24 | -$16.50M derived: sum of 2 quarters · filed 2025-04-24 | $3.20M derived: sum of 3 quarters · filed 2025-04-24 | |
| 2024-12-31 | -$19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $700.00K derived: sum of 2 quarters · filed 2025-02-18 | $1.80M 10-K · filed 2025-02-18 | |
| 2024-09-30 | $19.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-24 | $20.80M 10-Q · filed 2024-10-24 | ||
| 2024-06-30 | $1.10M 10-Q · filed 2024-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |